Heron Therapeutics Inc HRTX

NAS: HRTX | ISIN: US4277461020   26/04/2024
2,450 USD (-3,92%)
(-3,92%)   26/04/2024

24 april 2024 · Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 · Persbericht

11 april 2024 · Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City · Persbericht

28 maart 2024 · Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference · Persbericht

12 maart 2024 · Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates · Persbericht

28 februari 2024 · Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 · Persbericht

24 januari 2024 · Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures · Persbericht

7 januari 2024 · Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain · Persbericht

7 november 2023 · Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023 · Persbericht

14 augustus 2023 · Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Updates · Persbericht

7 augustus 2023 · Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023 · Persbericht

24 juli 2023 · Heron Therapeutics Announces Cost Reduction Plan and Restructuring · Persbericht

24 juli 2023 · Heron Therapeutics Announces $30 Million Private Placement Financing · Persbericht

23 juni 2023 · Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer · Persbericht

12 juni 2023 · Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Chief Development Officer · Persbericht

11 mei 2023 · Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates · Persbericht

4 mei 2023 · Heron Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 · Persbericht

20 april 2023 · Heron Therapeutics Announces Commercial Leadership Changes · Persbericht

17 april 2023 · Heron Therapeutics Announces Presentation at 22nd Annual Needham Virtual Healthcare Conference · Persbericht

3 april 2023 · Heron Therapeutics Announces New CEO and Board Chairman · Persbericht

23 maart 2023 · Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Highlights Recent Corporate Updates · Persbericht

Mijn selecties